Renoprotection for TAVI-Patients with renal dysfunction through remote ischemic preconditioning (rIPC)

Renoprotection for TAVI-Patients with renal dysfunction through remote ischemic preconditioning (rIPC) - RenTAVI

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

DRKS

Registry ID

DRKS00017553

Enrollment

100

Registered

2020-03-02

Start date

2020-02-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N14.2 N18.9

Interventions

Group 1: rIPC: 4 x 5 minutes of upper arm ischemia with 5 minutes reperfusion Group 2: Control: Standard procedure

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: transcatheter aortic valve Implantation (TAVI), renal dysfunction defined as Serum creatinine >123,76 µmol/l or GFR <60 ml/min/1,73m² calculated with CKD-EPI formula, informed consent

Exclusion criteria

Exclusion criteria: Dialysis

Design outcomes

Primary

Measure	Time frame
Incidence of contrast-induced nephropathy defined as increase of Serum creatinine = 44 µmol/l or = 25% above baseline within 48 h	—

Secondary

Measure	Time frame
maximum increase of serum creatinine, Serum Cystatine C and urinary NGAL, dialysis and death	—

Countries

Germany

Contacts

Public ContactEvren Caglayan

Universitätsmedizin Rostock, Zentrum für Innere Medizin, Abteilung Kardiologie

evren.caglayan@med.uni-rostock.de+49 381 494 7701

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026